Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Alnylam And Roche Initiated KARDIA-3 Phase 2 Study Of Zilebesiran Used As An Add-on Therapy For High Cardiovascular Risk And Uncontrolled Hypertension Despite Treatment With Two To Four Standard Antihypertensive Medications

Author: Benzinga Newsdesk | March 05, 2024 08:42am

Posted In: ALNY RHHBY

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist